AU · rank #7 · 2026-07-20
NANO
PARIS · EUR · $1.91B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.768 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.12 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $52.20 | +58.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +18.85% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | — |
| Gross margin TTM | +100.0% |
| 52w high | $47.66 |
| Market cap (USD) | $1.91B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Nanobiotix is a late-stage French biotech developing the radioenhancer NBTXR3 (JNJ-1900) with Johnson & Johnson, plus a second nanoparticle delivery platform called Curadigm.
Rationale
The screen is reinforced by clear analyst upside, recent upward EPS revisions, unanimous revision agreement, and improving clinical/news flow after positive CONVERGE data and a materially stronger cash runway from the recent financings.
Material risks
- 1NBTXR3 still hinges on late-stage trial success and J&J execution, so any Phase II/III setback or partnership reprioritization would quickly compress the upside case.
- 2Nanobiotix remains pre-commercial with no product revenue backlog, so the stock can still trade more on biotech sentiment and dilution/risk capital than on recurring fundamentals.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.